02:25 , Nov 11, 2015 |  BC Extra  |  Top Story

Astellas buying Ocata for $379M

Astellas Pharma Inc. (Tokyo:4503) announced late Monday night that it will acquire cell therapy company Ocata Therapeutics Inc. (NASDAQ:OCAT) for $8.50 per share, or $379 million in cash. The price represents a 91% premium to...
08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Transfusion Major histocompatibility complex class I A (HLA-A); HLA-B; HLA-C In vitro and mouse studies suggest transfusion with HLA-A/B/C- platelets generated from induced pluripotent stem...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Advanced Cell Technology management update

Advanced Cell Technology Inc. (OTCBB:ACTC), Marlborough, Mass.   Business: Gene/Cell therapy, Cardiovascular, Ophthalmic   Hired: LeRoux Jooste as SVP of business development, a newly created position, and chief commercial officer, formerly SVP and general manager...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

MA09-hRPE cells: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 9 SMD patients ages >18 who received sub-retinal transplantation of MA09-hRPE cells in 1 eye showed no adverse safety issues related to the transplanted tissue and confirmed...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

MA09-hRPE cells: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 9 dry AMD patients ages >55 who each received sub-retinal transplantation of MA09-hRPE cells in 1 eye showed no adverse safety issues related to the transplanted tissue...
03:27 , Oct 16, 2014 |  BC Extra  |  Clinical News

ACT boosted on stem cell results

Advanced Cell Technology Inc. (OTCBB:ACTC) held most of the gain it picked up ahead of Wednesday's online publication of data from a pair of Phase I/II trials showing visual improvements in patients treated with the...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

Advanced Cell Technology financial update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif.   Business: Gene/Cell therapy, Cardiovascular, Ophthalmic   Date announced: 2014-08-27   Note: Advanced Cell Technology implemented a 1-for-100 reverse stock split. Following the split, the company has...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

Advanced Cell Technology financial update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif.   Business: Gene/Cell therapy, Cardiovascular, Ophthalmic   Date announced: 2014-07-03   Note: Advanced Cell entered into a three-year, $30 million stock purchase agreement with Lincoln Park Capital....
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Advanced Cell Technology management update

Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif.   Business: Gene/Cell therapy, Cardiovascular, Ophthalmic   Hired: Paul Wotton as president and CEO, formerly president and CEO of Antares Pharma Inc.  ...
08:00 , Feb 27, 2014 |  BC Innovations  |  Tools & Techniques

(Pluri)potent acid

Academics and companies alike are scrambling-and thus far failing-to reproduce a surprisingly simple method for generating pluripotent mouse stem cells that uses an external stress stimulus to trigger reprogramming. Whether the method simply does not...